Abstract
The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have